{
  "markdown": " BD Alaris Infusion Central (Update A) \\| CISA A A ( Lock ) or[\\#protect2024](/protect2024)  Search Menu Close[Faith\\-Based Community](/audiences/faith-based-community) [High\\-Risk Communities](/audiences/high-risk-communities)* Resources \\& Tools[Resources \\& Tools](/resources-tools) [All Resources \\& Tools](/resources-tools/all-resources-tools)* News \\& Events[News \\& Events](/news-events) [Cybersecurity Alerts \\& Advisories](/news-events/cybersecurity-advisories)[Benefits \\& Perks](/careers/benefits-perks)[Resume \\& Application Tips](/careers/resume-application-tips)[Students \\& Recent Graduates](/students-recent-graduates-employment-opportunities)[Divisions \\& Offices](/about/divisions-offices)[\\#protect2024](/protect2024) 2. [News \\& Events](/news-events)4. [ICS Medical Advisory](/news-events/cybersecurity-advisories?f%5B0%5D=advisory_type%3A96) ICS Medical AdvisoryBD Alaris Infusion Central (Update A)===================================== Last Revised February 23, 2023 Alert Code ICSMA\\-23\\-047\\-011\\. EXECUTIVE SUMMARY---------------------* **CVSS v3 7\\.3*** **ATTENTION:**  Low attack complexity* **Vendor:**  Becton, Dickinson and Company (BD)* **Equipment:**  Alaris Infusion Central**\\-\\-\\-\\-\\-\\-\\-\\-\\- Begin Update A part 1 of 2 \\-\\-\\-\\-\\-\\-\\-\\-\\-** * **Vulnerability:**  Storing Passwords in a Recoverable Format**\\-\\-\\-\\-\\-\\-\\-\\-\\- End Update A part 1 of 2 \\-\\-\\-\\-\\-\\-\\-\\-\\-** 2\\. UPDATE INFORMATION---------------------- This updated advisory is a follow\\-up to the original advisory titled ICSMA\\-23\\-047\\-01 BD Alaris Infusion Central that was published February 16, 2023, to the ICS webpage on www.cisa.gov/uscert.3\\. RISK EVALUATION------------------- Successful exploitation of this vulnerability could allow an attacker to obtain the database installation password and gain access to the Alaris Infusion Central database, resulting in disclosure of resident personal data.4\\. TECHNICAL DETAILS---------------------### 4\\.1 AFFECTED PRODUCTS The following BD software products are affected:* Alaris Infusion Central software versions 1\\.1 to 1\\.3\\.2, which are not sold in the U.S.\t+ Users who use BD Alaris PCU 8015 or BD Alaris Systems Manager are not impacted by this vulnerability.### 4\\.2 VULNERABILITY OVERVIEW**\\-\\-\\-\\-\\-\\-\\-\\-\\- Begin Update A part 2 of 2 \\-\\-\\-\\-\\-\\-\\-\\-\\-** **4\\.2\\.1 [STORING PASSWORDS IN A RECOVERABLE FORMAT CWE\\-257](https://cwe.mitre.org/data/definitions/257.html)****\\-\\-\\-\\-\\-\\-\\-\\-\\- End Update A part 2 of 2 \\-\\-\\-\\-\\-\\-\\-\\-\\-**  Alaris Infusion Central versions 1\\.1\u20131\\.3\\.2 may contain a recoverable password after installation, which could allow an attacker to disclose or tamper with resident personal data. Patient health data is not stored in the database, although some side installations may choose to store personal data.[CVE\\-2022\\-47376](http://web.nvd.nist.gov/view/vuln/detail?vulnId=CVE-2022-47376)  has been assigned to this vulnerability. A CVSS v3 base score of 7\\.3 has been assigned; the CVSS vector string is ( [AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:L](https://www.first.org/cvss/calculator/3.0#CVSS:3.0/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:L)  ).### 4\\.3 BACKGROUND* **CRITICAL INFRASTRUCTURE SECTORS:**  Healthcare and Public Health* **COUNTRIES/AREAS DEPLOYED:**  Deployed outside the U.S.* **COMPANY HEADQUARTERS LOCATION:**  United States### 4\\.4 RESEARCHER BD reported this vulnerability to CISA.### 5\\. MITIGATIONS BD is directly reaching out to the small group of customers who may be impacted by this vulnerability to initiate remediation. BD recommends the following mitigations and compensating controls to reduce risk associated with this vulnerability:* Change passwords periodically per best security practice.* Ensure physical access controls are in place; only authorized administrators should have access to the Alaris Infusion Central server. For additional information, refer to BD\u2019s [security bulletin](https://www.bd.com/en-us/about-bd/cybersecurity/bulletin/alaris-infusion-central-recoverable-password-vulnerability)  . CISA reminds organizations to perform proper impact analysis and risk assessment prior to deploying defensive measures. CISA also provides a section for [control systems security recommended practices](https://us-cert.cisa.gov/ics/Recommended-Practices)  on the ICS webpage at [cisa.gov/ics](https://cisa.gov/ics)  . Several CISA products detailing cyber defense best practices are available for reading and download, including [Improving Industrial Control Systems Cybersecurity with Defense\\-in\\-Depth Strategies](https://us-cert.cisa.gov/sites/default/files/recommended_practices/NCCIC_ICS-CERT_Defense_in_Depth_2016_S508C.pdf)  . Additional mitigation guidance and recommended practices are publicly available on the ICS webpage at [cisa.gov/ics](https://cisa.gov/ics)  in the technical information paper, [ICS\\-TIP\\-12\\-146\\-01B\\-\\-Targeted Cyber Intrusion Detection and Mitigation Strategies](https://www.cisa.gov/uscert/ics/tips/ICS-TIP-12-146-01B)  . Organizations observing suspected malicious activity should follow established internal procedures and report findings to CISA for tracking and correlation against other incidents. CISA also recommends users take the following measures to protect themselves from social engineering attacks:* Do not click web links or open attachments in unsolicited email messages.* Refer to [Recognizing and Avoiding Email Scams](https://www.cisa.gov/uscert/sites/default/files/publications/emailscams_0905.pdf)  for more information on avoiding email scams.* Refer to [Avoiding Social Engineering and Phishing Attacks](https://www.cisa.gov/uscert/ncas/tips/ST04-014)  for more information on social engineering attacks. No known public exploits specifically target this vulnerability. This vulnerability is not exploitable remotely. This product is provided subject to this [Notification](/notification \"Follow link\")  and this [Privacy \\& Use](/privacy-policy \"Follow link\")  policy.-------------------------- [product survey](https://www.surveymonkey.com/r/CISA-cyber-survey?product=https://www.cisa.gov/news-events/ics-medical-advisories/icsma-23-047-01)  ; Related Advisories------------------ Jul 18, 2024 ICS Medical Advisory \\| ICSMA\\-24\\-200\\-01### [Philips Vue PACS](/news-events/ics-medical-advisories/icsma-24-200-01) Jun 11, 2024 ICS Medical Advisory \\| ICSMA\\-24\\-163\\-01### [MicroDicom DICOM Viewer](/news-events/ics-medical-advisories/icsma-24-163-01) May 30, 2024 ICS Medical Advisory \\| ICSMA\\-24\\-151\\-02### [Baxter Welch Allyn Connex Spot Monitor](/news-events/ics-medical-advisories/icsma-24-151-02) May 30, 2024 ICS Medical Advisory \\| ICSMA\\-24\\-151\\-01### [Baxter Welch Allyn Configuration Tool](/news-events/ics-medical-advisories/icsma-24-151-01)* [Resources \\& Tools](/resources-tools)* [News \\& Events](/news-events)[Cybersecurity \\& Infrastructure Security Agency](/ \"Go to the Cybersecurity & Infrastructure Security Agency homepage\")[1\\-844\\-Say\\-CISA](tel:1-844-Say-CISA) * [Equal Opportunity \\& Accessibility](/oedia \"Equal Opportunity & Accessibility\")",
  "cves": [
    "CVE-2022-47376"
  ],
  "techniques": [],
  "advisory": "icsma-23-047-01",
  "title": "BD Alaris Infusion Central (Update A) | CISA",
  "source": "ics-medical-advisories",
  "id": "ae8a55e38e0e77ee836e5d49d4ad3526fd54888081111366a22feb5ffda4a3ae"
}